Navigation Links
Lilly Reports Third-Quarter 2013 Results
Date:10/23/2013

e non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles ("GAAP").  The items that we exclude when we provide non-GAAP measures or expectations are typically highly variable, difficult to predict, and of a size that could have a substantial impact on our reported operations for a period. We believe that these non-GAAP measures provide useful information to investors.  Among other things, they may help investors evaluate our ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets.  Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.(b)Operating expenses include research and development, marketing, selling and administrative expenses.(c)Certain GAAP reported measures have been adjusted to eliminate asset impairments, restructuring and other special charges.  During the three months ended September 30, 2012, amounts totaling $53.3 million (pretax), or $0.04 per share (after-tax), of expense were eliminated primarily related to the asset impairment of a delivery device platform. (d)Certain GAAP reported measures have been adjusted to eliminate a portion of other income (expense).  During the three months ended September 30, 2012, amounts totaling $787.8 million (pretax), or $0.43 per share (after-tax) were eliminated from other income related to the termination of the exenatide collaboration with Amylin. 

Eli Lilly and CompanyReconciliation of GAAP Reported to Selected Non-GAAP Adjusted
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
2. Lilly Declares Fourth-Quarter 2013 Dividend
3. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
4. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
5. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
7. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
8. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
9. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
11. Lilly Reports Second-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... upcoming prestigious Minimally Invasive Surgery Symposium (MISS) will include ... to colon surgery, single-port bariatric surgery, transoral gastroplasty, and ... made today by MISS Executive Director Philip R Schauer, ... faculty. , The five-day CME conference, which will ...
... Calif., Oct. 27 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... teleconference with management to provide a general business overview, as ... Tuesday, November 3, 2009, at 5:00 p.m. Eastern Time (2:00 ... ended September 30, 2009 will be released earlier that day. ...
Cached Medicine Technology:Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego 2
(Date:4/18/2014)... a brain-related discovery that could revolutionize doctors, perception ... opens up the possibility that environmental and/or genetic ... activity that the researchers have identified as helping ... Neuroscience has just published a paper about ... of psychology and his doctoral student John Gaspar, ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2
... together nine research groups from seven countries, including teams ... and Israel, has recently been set up with the ... active sensing adopted widely in the animal kingdom, the ... ,whiskered, robotic rat. The whiskered robot will be able ...
... Medical Directions, Inc. (MDI),an independent digital medical education ... education program dealing with the,management of chronic pain ... live lectures by national experts., The study, ... Neurological,Disorders and Stroke (NINDS), was reported February 5, ...
... as better informed patients make ever-increasing demands and expect ... decisions that directly affect their care. In a ... Dr. J. Bohannon Mason of the Orthocarolina Hip and ... changes in society, the population and technology that are ...
... for Second Consecutive Year, STAMFORD, Conn., Feb. ... packaging and marketing process management,service, today announced it ... a,row by the readers of Consumer Goods Technology ... year, Paxonix was recognized with a,Best in Class ...
... Lumenis(R) Ltd. announced,today that it has scheduled a special ... accordance with the Israeli Companies,Law, of a proposed settlement ... against the Company in the federal court in New ... which has been,agreed to in principle by Lumenis and ...
... Financial Team, METAIRIE, La., Feb. 11 ... and dental practices,worldwide, has named Michael P. Beland ... responsible for all aspects of the Company,s,accounting, tax, ... am pleased that we have been able to ...
Cached Medicine News:Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 2Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 3Health News:Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts 2Health News:Doctor who? Are patients making clinical decisions? 2Health News:Paxonix Recognized for Exemplary Support in New Product Development and Implementation 2Health News:Lumenis(R) Seeks Shareholder Approval of Proposed Class Action Settlement 2Health News:Michael Beland Named as OrthoSynetics(TM) Corporate Controller 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: